Evaxion Biotech A/S (EVAX) Financials

EVAX Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 28.4 million 11.4 million
Sept. 30, 2025 29.7 million 13.1 million
June 30, 2025 22.4 million 16.2 million
March 31, 2025 25.2 million 14.9 million

EVAX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -6.7 million ?
Sept. 30, 2025 ? ?
June 30, 2025 ? ?
March 31, 2025 ? 357000

EVAX Net Income

No data available :(

EVAX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 23.2 million 5.3 million 1.6 million
Sept. 30, 2025 10.6 million - -
June 30, 2025 14.7 million 9.0 million 2.1 million
March 31, 2025 17.8 million - -

EVAX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 6.4 million
Sept. 30, 2025 1.1 million
June 30, 2025 1.1 million
March 31, 2025 1.1 million

EVAX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 11034 2.6 million 1.2 million -
Sept. 30, 2025 - 3.1 million 1.4 million -
June 30, 2025 - 2.2 million 2.2 million -
March 31, 2025 - 2.2 million 1.7 million -

EVAX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 22040 -
Sept. 30, 2025 7.5 million -
June 30, 2025 37000 -
March 31, 2025 122000 -

EVAX

Price: $3.55

52 week price:
2.07
12.15

Earnings Per Share: -1.00 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Denmark

Volume: 302177

Market Capitalization: 22.4 million

Links: